Clinical Collaboration

Selected news for the healthcare topic - Clinical Collaboration, collected since 10/2017. Recent stories appear in Yahoo News. This healthcare topic shares news with Merck, Bristol-Myers, Bristol-Myers Squibb, Gilead, Prostate Cancer and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/9/2021 Beam Therapeutics (NASDAQ:BEAM) versus CRISPR Therapeutics (NASDAQ:CRSP) Head-To-Head Comparison baseballnewssource.com ... develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.About CRISPR Therapeutics ...
5/6/2021 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 Yahoo News ... expect to provide a clinical update in the fourth quarter of this calendar year," said Dr. David R. Parkinson , M.D., President and Chief Executive Officer of ESSA Pharma. "During the quarter, we also announced clinical collaboration s with Janssen and Astellas, and recently on April 28 th entered into a partnership with Bayer, all focused on evaluating EPI-7386 in Phase 1/2 clinical studies in combination with their respective anti-androgen ...
4/22/2021 The NOBLE Registry – an international collaboration to develop iPSMA SPECT imaging for prostate cancer dotmed.com ... access, and Telix Pharmaceuticals Limited (‘Telix’), a radiopharmaceutical company developing diagnostic and therapeutic products (‘theranostics’) using Molecularly Targeted Radiation (MTR), are pleased to announce the launch of the NOBLE Registry, an international clinical collaboration for the development of 99mTc-iPSMA SPECT imaging for prostate cancer, and the dosing of the first patient at the University College Hospital, Ibadan, Nigeria.Prostate cancer is the second most frequent cancer diagnosis ...
4/19/2021 Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study Yahoo News ... 10) among othersHumanigen now plans to conduct a randomized, potentially registrational, Phase 2 study with lenzilumab combined with all commercially available CD19 CAR-T therapies in DLBCLHumanigen has terminated the ZUMA-19 clinical collaboration agreement with Kite, a Gilead CompanyHumanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate ...
4/19/2021 Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study Yahoo News ... 10) among othersHumanigen now plans to conduct a randomized, potentially registrational, Phase 2 study with lenzilumab combined with all commercially available CD19 CAR-T therapies in DLBCLHumanigen has terminated the ZUMA-19 clinical collaboration agreement with Kite, a Gilead CompanyHumanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate ...
4/15/2021 CAMBRIDGE, Mass. - April 15, 2021 - ( Newswire.c wapakdailynews.com ... with emergency, acute care and post-acute care with their flagship solution, Join, and other solutions, which are securely cloud-based, HIPAA-compliant and FDA-approved. In addition to enabling better care coordination and clinical collaboration , their solutions also seamlessly collect data and support research and quality improvement initiatives. Hospital teams and EMS teams use these solutions to improve patient outcomes and safety, reduce clinician burden, bring in new revenue ...
4/8/2021 New York State Approves Affiliation Between Maimonides Medical Center and New York Community Hospital Business Insider ... The affiliation draws on the historic strength of both hospitals, facilitating further collaboration among clinicians and more convenient patient access to a broader array of medical and surgical specialty services at NYCH.Through their existing clinical collaboration agreement, Maimonides and NYCH have already demonstrated ways in which the relationship benefits patients. Maimonides physicians from over ten specialties have begun to provide services at NYCH. The two organizations are also in the ...
4/8/2021 NYS Approves Affiliation Between Maimonides Medical Center and NY Community Hospital hamodia.com ... affiliation draws on the historic strength of both hospitals, facilitating further collaboration among clinicians and more convenient patient access to a broader array of medical and surgical specialty services at NYCH.Through their existing clinical collaboration agreement, Maimonides and NYCH have already demonstrated ways in which the relationship benefits patients. Maimonides physicians from over ten specialties have begun to provide services at NYCH. The two organizations are also in the ...
4/7/2021 PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration | Business Wire Business Wire OXFORD, England--( BUSINESS WIRE )--PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo ® (nivolumab) to treat a range of tumor types in late-stage cancer patients.The first stage of ...
4/7/2021 PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration Yahoo News PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo ® (nivolumab) to treat a range of tumor types in late-stage cancer patients.The first stage of this collaboration combined Bristol ...
4/7/2021 The Ridgway Record ridgwayrecord.com PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb ( NYSE: BMY ) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo ® (nivolumab) to treat a range of tumor types in late-stage cancer patients.The first stage of this collaboration combined Bristol ...
4/7/2021 malvern-online.com PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb ( NYSE: BMY ) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo ® (nivolumab) to treat a range of tumor types in late-stage cancer patients.The first stage of this collaboration combined Bristol ...
4/7/2021 PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration firstwordpharma.com PrintOXFORD, England--( BUSINESS WIRE )-- PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus' tumor re-engineering platform, in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo ® (nivolumab) to treat a range of tumor types in late-stage cancer patients.The first stage of this ...
4/6/2021 ORYZON Starts Preclinical Collaboration on Autism with the Seaver Autism Center at Mount Sinai Madrid Stock Exchange:ORY.MC bollyinside.com Globenewswire 2021-04-06 Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models MADRID, Spain and CAMBRIDGE, Mass., April 06, 2021 (News) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration on autism with researchers from the Seaver ...
4/5/2021 Clinical Collaboration Systems for Hospitals—Complete Guide perfectserve.com ... have identified an opportunity for improvement. Fortunately, healthcare technology has come a long way in a short period of time, and it is easier than ever to replace siloed tools and systems with integrated clinical collaboration solutions. What are the top digital solutions for clinical communication? The simplest answer is: It depends. There are various clinical collaboration tools that exist to serve specific purposes. Since each health system, hospital, and ...
4/1/2021 Actinium to Participate in the Cell & Gene Meeting on the Mediterranean firstwordpharma.com ... Iomab-ACT uses a lower dose of radiation, intended to achieve lymphodepletion for CAR-T and other adoptive cell therapies or reduced intensity conditioning for gene therapies.Iomab-ACT is being utilized in a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") for targeted conditioning with MSK's CD19 targeting CAR T-cell therapy 19-28z for patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Actinium and MSK were ...
4/1/2021 Actinium to Participate in the Cell & Gene Meeting on the Mediterranean Business Insider ... Iomab-ACT uses a lower dose of radiation, intended to achieve lymphodepletion for CAR-T and other adoptive cell therapies or reduced intensity conditioning for gene therapies. Iomab-ACT is being utilized in a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") for targeted conditioning with MSK's CD19 targeting CAR T-cell therapy 19-28z for patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Actinium and MSK were ...
3/30/2021 Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma PR Newswire SAN DIEGO , March 30, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY ) to evaluate the combination of HUYABIO's HBI-8000, an epigenetic immunomodifier, and Opdivo ® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy ...
3/29/2021 CAMBRIDGE, Mass., NEWSWIRE) wapakdailynews.com ... broaden and accelerate our CMP-001 clinical program in melanoma and other solid tumor indications,” said Barry Labinger, President and Chief Executive Officer of Checkmate.Recent ProgressIn December 2020, Checkmate announced a clinical collaboration with Bristol Myers Squibb to evaluate vidutolimod (formerly CMP-001) in combination with nivolumab. The companies will collaborate on two melanoma clinical trials. In January 2021, Checkmate appointed Robert F. Dolski as Chief Financial ...
3/29/2021 Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger Benzinga ... monotherapy dose-expansion and combination studies are expected in 2022. TPST-1120 has completed monotherapy dose-escalation and is progressing through a combination dose-escalation study with nivolumab. Earlier this month, Tempest announced a clinical collaboration with Roche to investigate TPST-1120 in a randomized frontline hepatocellular carcinoma study. Topline data from this study by year-end 2022. In support of the merger, Tempest has secured commitments from a syndicate ...